Drug intelligence / Profile preview

Engineered Treg

Development stage: Preclinical
Lead developer: Taiwan Bio Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

Engineered Treg is a preclinical-stage cell therapy being developed by TaiwanBio Therapeutics for the treatment of autoimmune diseases. This therapeutic candidate utilizes the company's proprietary FAST CGT platform to genetically modify regulatory T cells (Tregs), aiming to enhance their stability, specificity, or immunosuppressive potency. By leveraging the natural role of Tregs in maintaining immune homeostasis, the therapy is designed to restore self-tolerance and modulate the aberrant immune responses that drive various autoimmune conditions.

Other names: Engineered regulatory T cell therapyTaiwanBio Therapeutics Engineered Treg

Beyond the preview

Go deeper on Engineered Treg.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Engineered Treg.

Explore the full profile